4-(Methylsulfonyl)phenylacetic Acid CAS 90536-66-6 Purity >99.0% (HPLC) Etoricoxib Intermediate Factory

Short Description:

Chemical Name: 4-(Methylsulfonyl)phenylacetic Acid

CAS: 90536-66-6

Purity: >99.0% (HPLC)

Appearance: White to Off-White Solid Powder

Intermediate of Etoricoxib (CAS: 202409-33-4)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

90536-66-6 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-(Methylsulfonyl)phenylacetic Acid (CAS: 90536-66-6) with high quality, an important intermediate of Etoricoxib (CAS: 202409-33-4).
Etoricoxib is widely used in the treatment of osteoarthritis (OA), acute gouty arthritis, and other diseases.
Ruifu Chemical has been supplying pharmaceutical intermediates and APIs more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Etoricoxib intermediates, Please contact: alvin@ruifuchem.com

Intermediates of Etoricoxib (CAS: 202409-33-4):

Etoricoxib API	CAS 202409-33-4
4-(Methylthio)phenylacetic Acid	CAS 16188-55-9
4-(Methylsulfonyl)phenylacetic Acid	CAS 90536-66-6
Methyl 6-Methylnicotinate	CAS 5470-70-2
1-(6-Methylpyridin-3-yl)-2-[4-(Methylthio)phenyl]ethanone	CAS 221615-72-1
1-(6-Methylpyridin-3-yl)-2-[4-(Methylsulfonyl)phenyl]ethanone	CAS 221615-75-4
2-Chloro-1,3-Bis(dimethylamino)trimethinium Hexafluorophosphate	CAS 249561-98-6 ; 291756-76-8

90536-66-6 - Chemical Properties:

Chemical Name	4-(Methylsulfonyl)phenylacetic Acid
Synonyms	4-Methylsulphonylphenylacetic Acid; 4-(Methanesulfonyl)phenylacetic Acid; (4-Methanesulfonylphenyl)acetic Acid; 4-Methylsulfonyl Phenyl Acetic Acid; 2-(4-(Methylsulfonyl)phenyl)acetic Acid; [p-(Methylsulfonyl)phenyl]-Acetic Acid; 4-Mesylphenylacetic Acid
CAS Number	90536-66-6
Stock Status	In Stock, Commercial Production
Molecular Formula	C9H10O4S
Molecular Weight	214.24
Melting Point	136.0 to 140.0℃
Density	1.35
Solubility	Soluble in Methanol
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	Pharmaceutical Intermediates
Brand	Ruifu Chemical

90536-66-6 - Specifications:

Item	Specifications	Results
Appearance	White to Off-White Solid Powder	Off-White Solid Powder
Purity / Analysis Method	>99.0% (HPLC)	99.91% (HPLC)
Melting Point	136.0~140.0℃	137.0~139.0℃
Moisture (K.F)	<0.50%	0.25%
Single Largest Impurity	<0.50%	0.06%
Total Impurities	<1.00%	0.09%
Infrared Spectrum	Conforms to Structure	Conforms
Conclusion	This product by inspection accords with the Enterprise Standard
Conclusion	Intermediate of Etoricoxib (CAS: 202409-33-4)

90536-66-6 - Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

90536-66-6 - Advantages:

90536-66-6 - FAQ:

90536-66-6 - Risk and Safety:

Hazard Symbols Xi - Irritant
Risk Codes 36 - Irritating to the eyes
Safety Description
26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany 3
HS Code 2930909099
Hazard Note Irritant

90536-66-6 - Application:

4-(Methylsulfonyl)phenylacetic Acid (CAS: 90536-66-6) is an intermediate of Etoricoxib (CAS: 202409-33-4). Etoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company. Etoricoxib is widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases. Etoricoxib, a selective COX-2 inhibitor, has anti-inflammatory, analgesic and antipyretic effects, suitable for the treatment of symptoms and signs of acute and chronic osteoarthritis, as well as acute gouty arthritis. Etoricoxib is rapidly absorbed, with an oral bioavailability of 80 to 100%, and reaches maximum plasma concentrations in 1 to 2 hours after dosing. Food decreases the rate of absorption but has no effect on the extent of absorption. It exhibits a long elimination half-life of approximately 22 hours, demonstrating linear plasma pharmacokinetics with no accumulation during multiple dosing.